Free Trial
NASDAQ:PMCB

PharmaCyte Biotech 7/31/2023 Earnings Report

PharmaCyte Biotech logo
$1.07 +0.06 (+5.92%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$1.05 -0.02 (-2.15%)
As of 05/28/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PharmaCyte Biotech EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PharmaCyte Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PharmaCyte Biotech Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PharmaCyte Biotech's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

PharmaCyte Biotech Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
PharmaCyte Biotech Inc PMCB
See More PharmaCyte Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PharmaCyte Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PharmaCyte Biotech and other key companies, straight to your email.

About PharmaCyte Biotech

PharmaCyte Biotech (NASDAQ:PMCB), a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View PharmaCyte Biotech Profile

More Earnings Resources from MarketBeat